

# 83-6-02 85



## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/723,713

DATE: 03/06/2002

TIME: 10:07:15

Input Set : N:\Crif3\RULE60\09723713.txt

Output Set: N:\CRF3\03062002\I723713.raw

3 <110> APPLICANT: Schenk, Dale B.  
 4 Neuralab Limited  
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
 8 <130> FILE REFERENCE: 15270J-004740US  
 10 <140> CURRENT APPLICATION NUMBER: 09/723,713  
 11 <141> CURRENT FILING DATE: 2000-11-27  
 13 <150> PRIOR APPLICATION NUMBER: 09/322,289  
 14 <151> PRIOR FILING DATE: 1999-05-28  
 16 <160> NUMBER OF SEQ ID NOS: 5  
 18 <170> SOFTWARE: PatentIn Ver. 2.1  
 20 <210> SEQ ID NO: 1  
 21 <211> LENGTH: 42  
 22 <212> TYPE: PRT  
 23 <213> ORGANISM: Homo sapiens  
 25 <220> FEATURE:  
 26 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide  
 28 <400> SEQUENCE: 1  
 29 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
 30 1 5 10 15  
 32 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
 33 20 25 30  
 35 Gly Leu Met Val Gly Gly Val Val Ile Ala  
 36 35 40  
 39 <210> SEQ ID NO: 2  
 40 <211> LENGTH: 13  
 41 <212> TYPE: PRT  
 42 <213> ORGANISM: Artificial Sequence  
 44 <220> FEATURE:  
 45 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-12  
 46 peptide with carboxyl terminal Cys residue  
 47 inserted  
 49 <400> SEQUENCE: 2  
 50 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys  
 51 1 5 10  
 54 <210> SEQ ID NO: 3  
 55 <211> LENGTH: 6  
 56 <212> TYPE: PRT  
 57 <213> ORGANISM: Artificial Sequence  
 59 <220> FEATURE:  
 60 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-5  
 61 peptide with carboxyl terminal Cys residue  
 62 inserted  
 64 <400> SEQUENCE: 3

ENTERED

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/723,713

DATE: 03/06/2002

TIME: 10:07:15

Input Set : N:\Crf3\RULE60\09723713.txt

Output Set: N:\CRF3\03062002\I723713.raw

```

65 Asp Ala Glu Phe Arg Cys
66   1                               5
69 <210> SEQ ID NO: 4
70 <211> LENGTH: 12
71 <212> TYPE: PRT
72 <213> ORGANISM: Artificial Sequence
74 <220> FEATURE:
75 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta33-42
76     peptide with carboxyl terminal Cys residue
77     inserted
79 <220> FEATURE:
80 <221> NAME/KEY: MOD_RES
81 <222> LOCATION: (2)
82 <223> OTHER INFORMATION: Xaa = amino heptanoic acid
84 <400> SEQUENCE: 4
W--> 85 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
86   1                               5                               10
89 <210> SEQ ID NO: 5
90 <211> LENGTH: 19
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
96     peptide with carboxyl terminal Cys residue
97     inserted and two added Gly residues
99 <220> FEATURE:
100 <221> NAME/KEY: MOD_RES
101 <222> LOCATION: (1)
102 <223> OTHER INFORMATION: Xaa = acetyl histidine
104 <400> SEQUENCE: 5
W--> 105 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
106   1                               5                               10                               15
108 Gly Gly Cys

```

**VERIFICATION SUMMARY**

PATENT APPLICATION: US/09/723,713

DATE: 03/06/2002

TIME: 10:07:16

Input Set : N:\Crf3\RULE60\09723713.txt

Output Set: N:\CRF3\03062002\I723713.raw

L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4

L:105 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5